ACXP - חוב כולל להון Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals focuses on developing antibiotics to combat superbugs, targeting the hospital sector and C. difficile therapy. This chart of share price dynamics illustrates a total debt-to-equity ratio of 0.00. The company is currently developing innovative drugs within clinical trials. To achieve these objectives, the business is recruiting leading microbiologists interested in fighting resistant infections.

To stress-test assets, an investor evaluates the ratio of total liabilities to equity to determine the business's level of dependence on creditors. In the context of developing unique, patent-protected antibiotics, the balance between debt and equity demonstrates how the financial burden aligns with the pace of creating a technological barrier, confirming the resilience of Acurx Pharmaceuticals (ACXP) to market shocks.